Abstract | BACKGROUND: METHODS: We did a population-based case-control study of linked administrative databases in Ontario, Canada. The sample included consecutive patients older than 65 (n=15,326) admitted to hospital with a primary diagnosis of ruptured or intact abdominal aortic aneurysm between April 1, 1992, and April 1, 2002. FINDINGS: Patients who received ACE inhibitors before admission were significantly less likely to present with ruptured aneurysm (odds ratio [OR] 0.82, 95% CI 0.74-0.90) than those who did not receive ACE inhibitors. Adjustment for demographic characteristics, risk factors for rupture, comorbidities, contraindications to ACE inhibitors, measures of health-care use, and aneurysm screening yielded similar results (0.83, 0.73-0.95). Consistent findings were noted in subgroups at high risk of rupture, including patients older than 75 years and those with a history of hypertension. Conversely, such protective associations were not observed for beta blockers (1.02, 0.89-1.17), calcium channel blockers (1.01, 0.89-1.14), alpha blockers (1.15, 0.86-1.54), angiotensin receptor blockers (1.24, 0.71-2.18), or thiazide diuretics (0.91, 0.78-1.07). INTERPRETATION:
|
Authors | Daniel G Hackam, Deva Thiruchelvam, Donald A Redelmeier |
Journal | Lancet (London, England)
(Lancet)
Vol. 368
Issue 9536
Pg. 659-65
(Aug 19 2006)
ISSN: 1474-547X [Electronic] England |
PMID | 16920471
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiotensin-Converting Enzyme Inhibitors
|
Topics |
- Aged
- Angiotensin-Converting Enzyme Inhibitors
(therapeutic use)
- Aortic Aneurysm, Abdominal
- Aortic Rupture
(mortality, prevention & control)
- Case-Control Studies
- Comorbidity
- Contraindications
- Databases, Factual
- Female
- Humans
- Logistic Models
- Male
- Middle Aged
- Ontario
- Retrospective Studies
|